Literature DB >> 31944498

Intrahepatic cholangiocarcinoma as a rare secondary malignancy after allogeneic hematopoietic stem cell transplantation for childhood acute lymphoblastic leukemia: A case report.

Meghan L Good1,2, Parisa Malekzadeh1,2, Isaac R Kriley1, Nirali N Shah3, David E Kleiner4, Katherine Calvo4, Jonathan M Hernandez1, Jeremy L Davis1.   

Abstract

Secondary malignancies are a significant cause of non-relapse mortality in patients who undergo allogeneic HCT. However, secondary liver cancer is rare, and ICC following HCT has never been reported in the literature. Secondary solid cancers typically have a long latency period, and cholangiocarcinoma is classically a malignancy occurring in older individuals. Here, we report the first case of secondary ICC, which presented just 3 years after HCT in a young adult with a history of childhood ALL. A 26-year-old male with history of precursor B-cell ALL presented with asymptomatic elevated liver function tests 3 years after HCT. Laboratories were indicative of biliary obstruction. ERCP showed focal biliary stricturing of the common and left hepatic ducts. MRCP revealed left intrahepatic duct dilatation, suggestive of intrahepatic obstructing mass. Additional workup lead to a clinical diagnosis of ICC. The patient underwent left hepatectomy with extrahepatic bile duct resection and portal lymphadenectomy. Surgical pathology was consistent with moderately differentiated cholangiocarcinoma. Our case illustrates a rare SMN following HCT for ALL. It is the first case report of ICC occurring as a secondary cancer in this patient population. Although cholangiocarcinoma is characteristically diagnosed in the older population, it must remain on the differential for biliary obstruction in post-HCT patients.
© 2020 Wiley Periodicals, Inc.

Entities:  

Keywords:  Intrahepatic cholangiocarcinoma; acute lymphoblastic leukemia; bone marrow transplant; case report; cholangiocarcinoma; hematopoietic stem cell transplant; secondary malignancy

Mesh:

Year:  2020        PMID: 31944498      PMCID: PMC8453586          DOI: 10.1111/petr.13653

Source DB:  PubMed          Journal:  Pediatr Transplant        ISSN: 1397-3142


  11 in total

Review 1.  Intrahepatic cholangiocarcinoma: management options and emerging therapies.

Authors:  Rebecca M Dodson; Matthew J Weiss; David Cosgrove; Joseph M Herman; Ihab Kamel; Robert Anders; Jean-Francois H Geschwind; Timothy M Pawlik
Journal:  J Am Coll Surg       Date:  2013-07-24       Impact factor: 6.113

2.  National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Subsequent Neoplasms Working Group Report.

Authors:  Lindsay M Morton; Wael Saber; K Scott Baker; A John Barrett; Smita Bhatia; Eric A Engels; Shahinaz M Gadalla; David E Kleiner; Steven Pavletic; Linda J Burns
Journal:  Biol Blood Marrow Transplant       Date:  2016-09-12       Impact factor: 5.742

Review 3.  Secondary solid cancer screening following hematopoietic cell transplantation.

Authors:  Y Inamoto; N N Shah; B N Savani; B E Shaw; A A Abraham; I A Ahmed; G Akpek; Y Atsuta; K S Baker; G W Basak; M Bitan; Z DeFilipp; T K Gregory; H T Greinix; M Hamadani; B K Hamilton; R J Hayashi; D A Jacobsohn; R T Kamble; K A Kasow; N Khera; H M Lazarus; A K Malone; M T Lupo-Stanghellini; S P Margossian; L S Muffly; M Norkin; M Ramanathan; N Salooja; H Schoemans; J R Wingard; B Wirk; W A Wood; A Yong; C N Duncan; M E D Flowers; N S Majhail
Journal:  Bone Marrow Transplant       Date:  2015-03-30       Impact factor: 5.483

Review 4.  Cholangiocarcinoma - evolving concepts and therapeutic strategies.

Authors:  Sumera Rizvi; Shahid A Khan; Christopher L Hallemeier; Robin K Kelley; Gregory J Gores
Journal:  Nat Rev Clin Oncol       Date:  2017-10-10       Impact factor: 66.675

5.  Childhood and adolescent cancer statistics, 2014.

Authors:  Elizabeth Ward; Carol DeSantis; Anthony Robbins; Betsy Kohler; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2014-01-31       Impact factor: 508.702

6.  Racial and ethnic variations in the epidemiology of intrahepatic cholangiocarcinoma in the United States.

Authors:  Luciana McLean; Tushar Patel
Journal:  Liver Int       Date:  2006-11       Impact factor: 5.828

Review 7.  Subsequent malignant neoplasms after hematopoietic cell transplantation.

Authors:  Gerard Socié; K Scott Baker; Smita Bhatia
Journal:  Biol Blood Marrow Transplant       Date:  2012-01       Impact factor: 5.742

8.  Subsequent neoplasms in 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study.

Authors:  Debra L Friedman; John Whitton; Wendy Leisenring; Ann C Mertens; Sue Hammond; Marilyn Stovall; Sarah S Donaldson; Anna T Meadows; Leslie L Robison; Joseph P Neglia
Journal:  J Natl Cancer Inst       Date:  2010-07-15       Impact factor: 11.816

9.  Twenty-five-year follow-up among survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study.

Authors:  Rajen Mody; Suwen Li; Douglas C Dover; Stephen Sallan; Wendy Leisenring; Kevin C Oeffinger; Yutaka Yasui; Leslie L Robison; Joseph P Neglia
Journal:  Blood       Date:  2008-03-11       Impact factor: 25.476

10.  Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise.

Authors:  Supriya K Saha; Andrew X Zhu; Charles S Fuchs; Gabriel A Brooks
Journal:  Oncologist       Date:  2016-03-21
View more
  2 in total

1.  Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL.

Authors:  Nirali N Shah; Daniel W Lee; Bonnie Yates; Constance M Yuan; Haneen Shalabi; Staci Martin; Pamela L Wolters; Seth M Steinberg; Eva H Baker; Cindy P Delbrook; Maryalice Stetler-Stevenson; Terry J Fry; David F Stroncek; Crystal L Mackall
Journal:  J Clin Oncol       Date:  2021-03-25       Impact factor: 44.544

Review 2.  Beyond the storm - subacute toxicities and late effects in children receiving CAR T cells.

Authors:  Haneen Shalabi; Juliane Gust; Agne Taraseviciute; Pamela L Wolters; Allison B Leahy; Carlos Sandi; Theodore W Laetsch; Lori Wiener; Rebecca A Gardner; Veronique Nussenblatt; Joshua A Hill; Kevin J Curran; Timothy S Olson; Colleen Annesley; Hao-Wei Wang; Javed Khan; Marcelo C Pasquini; Christine N Duncan; Stephan A Grupp; Michael A Pulsipher; Nirali N Shah
Journal:  Nat Rev Clin Oncol       Date:  2021-01-25       Impact factor: 66.675

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.